Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Efficacy of a cysteine protease inhibitor compared with enalapril in murine heart failure models

  • Aluja, David
  • Delgado Tomás, Sara
  • Ferreira González, Ignacio
  • Barrabés, José A.
  • miro casas, elisabet
  • Ruiz Meana, Marisol
  • Rodriguez-Sinovas, Antonio
  • Benito, Begoña
  • Inserte, Javier
Cardiovascular medicine; Cell biology, Medicina cardiovascular; Biologia cel·lular, Medicina cardiovascular; Biología celular, Cysteine proteases calpains contribute to heart failure (HF), but it remains unknown whether their inhibition provides any benefit compared to standard pharmacological treatment for HF. Here, we characterize the pharmacological properties of NPO-2270 (NPO) as a potent inhibitor of cysteine proteases. Then, we describe that acute administration of NPO in rodent models of transient ischemia at the time of reperfusion reduces myocardial infarction, while its chronic oral administration attenuates adverse remodeling and cardiac dysfunction induced by ischemic and non-ischemic pathological stimuli more effectively than enalapril when given at the same dose. Finally, we provide evidence showing that the effects of NPO correlate with calpain inhibition and the preservation of the T-tubule morphology, due at least in part to reduced cleavage of the calpain substrate junctophilin-2. Together, our data highlight the potential of cysteine protease inhibition with NPO as a therapeutic strategy for the treatment of heart failure., This work was funded by Instituto de Salud Carlos III, Spain, through the projects AES PI20/01681 and AES PI23/00068; and the research network CIBERCV (CB16/11/00479), both cofunded by European Regional Development Fund; Sociedad Española de Cardiología (SEC/FEC-INV-BAS 22/013); Fundació la Marató de TV3 (FLMTV3/202321-30-31) and PERIS STL/484/2023. Long-Sheng Song is supported by the National Institutes of Health of USA.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Mammalian TatD DNase domain containing 1 (TATDN1) is a proteostasis-responsive gene with roles in ventricular structure and neuromuscular function

  • Barés, Gisel
  • Beà Tàrrega, Aida
  • Sancho-Balsells, Anna
  • Valero, Juan Garcia
  • miro casas, elisabet
  • Ruiz Meana, Marisol
  • Aluja, David
  • Inserte, Javier
Cardiomyopathy; Motor control; Neurobehavior, Cardiomiopatía; Control motor; Neuroconducta, Cardiomiopatia; Control motor; Neuroconducta, The characterization of highly conserved but poorly understood genes often reveals unexpected biological roles, advancing our understanding of disease mechanisms. One such gene is Mammalian TatD DNase domain containing 1 (Tatdn1), the mammalian homolog of bacterial Twin-arginine translocation D (TatD), a protein proposed to have roles either in DNA degradation or protein quality control in unicellular organisms. Despite its association with different pathologies, including several cancer types and cardiovascular diseases, the role of TATDN1 in mammals remains unexplored. Here, we demonstrate that Tatdn1 encodes a cytoplasmic protein that does not participate in DNA degradation but is upregulated in cells under proteostasis stress. Tatdn1-deficient mice exhibit dysregulated expression of genes involved in membrane and extracellular protein biology, along with mild dilated cardiomyopathy and impaired motor coordination. These findings identify TATDN1 as a key player in cytosolic processes linked to protein homeostasis, with significant physiological implications for cardiac and neurological function., This research was funded by Ministerio de Ciencia, Innovación y Universidades, Gobierno de España, grant numbers PID2019-104509RB-I00 and PID2022-139965OB-100 to DS; Fundació La Marató TV3, grant number 20153810 to DS; AGAUR, Generalitat de Catalunya, grant number 2014-SGR-1609 to DS and JXC; GB holds a contract from the University of Lleida; AB holds a contract from Fundació La Marató TV3 and IRBLleida/Diputació de Lleida. SGC is the recipient of a FI Joan Oró contract from the Generalitat de Catalunya and co-financed by the European Social Fund Plus (FSE+) (AGAUR_2024_FI-1_00908) and AG is a Ramón y Cajal fellow (RYC-2016-19466) supported by a grant from Ministerio de Ciencia, Innovación y Universidades (PID2021-122258OB-I00). We thank the personnel of the University of Lleida Experimental Animal Service and Roser Pané for their technical assistance at IRBLleida and Ana López (María de Maeztu Unit of Excellence, Institute of Neurosciences, University of Barcelona, MDM-2017-0729, Ministerio de Ciencia, Innovación y Universidades) for technical support. We thank Dimitri Shcherbakov (Institut fur Medizinische Mikrobiologie, Universitat Zurich, Switzerland.) for his kind gift of HEK293 WT and RPS9 D95N mutant cells. JI and MRM are funded by Instituto de Salud Carlos III (ISCIII) (PI19-01196 and PI20-01681), CIBER-CV, and the European Regional Development Fundings (ERDF-FEDER). Work at The Novo Nordisk Foundation Center for Protein Research (CPR) is funded in part by a generous donation from the Novo Nordisk Foundation (Grant number NNF14CC0001) and from the European Union's Horizon 2020 research and innovation program under grant agreement EPIC-XS-823839.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Calpains as Potential Therapeutic Targets for Myocardial Hypertrophy

  • Aluja Gonzalez, David
  • Barrabés Riu, José Antonio
  • Inserte Igual, Javier
  • Ruiz Meana, Marisol
  • Delgado Tomás, Sara
Calpain; Calpastatin; Myocardial hypertrophy, Calpaína; Calpastatina; Hipertrofia miocárdica, Calpaïna; Calpastatina; Hipertròfia miocàrdica, Despite advances in its treatment, heart failure remains a major cause of morbidity and mortality, evidencing an urgent need for novel mechanism-based targets and strategies. Myocardial hypertrophy, caused by a wide variety of chronic stress stimuli, represents an independent risk factor for the development of heart failure, and its prevention constitutes a clinical objective. Recent studies performed in preclinical animal models support the contribution of the Ca2+-dependent cysteine proteases calpains in regulating the hypertrophic process and highlight the feasibility of their long-term inhibition as a pharmacological strategy. In this review, we discuss the existing evidence implicating calpains in the development of cardiac hypertrophy, as well as the latest advances in unraveling the underlying mechanisms. Finally, we provide an updated overview of calpain inhibitors that have been explored in preclinical models of cardiac hypertrophy and the progress made in developing new compounds that may serve for testing the efficacy of calpain inhibition in the treatment of pathological cardiac hypertrophy., This study was funded by the Instituto de Salud Carlos III of the Spanish Ministry of Health FIS-PI20/01681) and the research network CIBERCV (CB16/11/00479).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Ischemic postconditioning and duration of previous ischemia, Poscondicionamiento isquémico y duración de la isquemia previa

  • Barrabés, José A.
Ischemic postconditioning, Postcondicionament isquèmic, Postcondicionamiento isquémico, J.A. Barrabés received research funds from Instituto de Salud Carlos III (PI20/01681 project) and Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV) co-financed by the European Regional Development Fund.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Efficacy of a cysteine protease inhibitor compared with enalapril in murine heart failure models

  • Aluja, David
  • Delgado Tomás, Sara
  • Ferreira González, Ignacio
  • Barrabés, José A.
  • miro casas, elisabet
  • Ruiz Meana, Marisol
  • Rodriguez-Sinovas, Antonio
  • Benito, Begoña
  • Inserte, Javier
Cardiovascular medicine; Cell biology, Medicina cardiovascular; Biologia cel·lular, Medicina cardiovascular; Biología celular, Cysteine proteases calpains contribute to heart failure (HF), but it remains unknown whether their inhibition provides any benefit compared to standard pharmacological treatment for HF. Here, we characterize the pharmacological properties of NPO-2270 (NPO) as a potent inhibitor of cysteine proteases. Then, we describe that acute administration of NPO in rodent models of transient ischemia at the time of reperfusion reduces myocardial infarction, while its chronic oral administration attenuates adverse remodeling and cardiac dysfunction induced by ischemic and non-ischemic pathological stimuli more effectively than enalapril when given at the same dose. Finally, we provide evidence showing that the effects of NPO correlate with calpain inhibition and the preservation of the T-tubule morphology, due at least in part to reduced cleavage of the calpain substrate junctophilin-2. Together, our data highlight the potential of cysteine protease inhibition with NPO as a therapeutic strategy for the treatment of heart failure., This work was funded by Instituto de Salud Carlos III, Spain, through the projects AES PI20/01681 and AES PI23/00068; and the research network CIBERCV (CB16/11/00479), both cofunded by European Regional Development Fund; Sociedad Española de Cardiología (SEC/FEC-INV-BAS 22/013); Fundació la Marató de TV3 (FLMTV3/202321-30-31) and PERIS STL/484/2023. Long-Sheng Song is supported by the National Institutes of Health of USA.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Ischemic postconditioning and duration of previous ischemia, Poscondicionamiento isquémico y duración de la isquemia previa

  • Barrabés, José A.
Ischemic postconditioning, Postcondicionament isquèmic, Postcondicionamiento isquémico, J.A. Barrabés received research funds from Instituto de Salud Carlos III (PI20/01681 project) and Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV) co-financed by the European Regional Development Fund.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Calpains as Potential Therapeutic Targets for Myocardial Hypertrophy

  • Aluja Gonzalez, David
  • Barrabés Riu, José Antonio
  • Inserte Igual, Javier
  • Ruiz Meana, Marisol
  • Delgado Tomás, Sara
Calpain; Calpastatin; Myocardial hypertrophy, Calpaína; Calpastatina; Hipertrofia miocárdica, Calpaïna; Calpastatina; Hipertròfia miocàrdica, Despite advances in its treatment, heart failure remains a major cause of morbidity and mortality, evidencing an urgent need for novel mechanism-based targets and strategies. Myocardial hypertrophy, caused by a wide variety of chronic stress stimuli, represents an independent risk factor for the development of heart failure, and its prevention constitutes a clinical objective. Recent studies performed in preclinical animal models support the contribution of the Ca2+-dependent cysteine proteases calpains in regulating the hypertrophic process and highlight the feasibility of their long-term inhibition as a pharmacological strategy. In this review, we discuss the existing evidence implicating calpains in the development of cardiac hypertrophy, as well as the latest advances in unraveling the underlying mechanisms. Finally, we provide an updated overview of calpain inhibitors that have been explored in preclinical models of cardiac hypertrophy and the progress made in developing new compounds that may serve for testing the efficacy of calpain inhibition in the treatment of pathological cardiac hypertrophy., This study was funded by the Instituto de Salud Carlos III of the Spanish Ministry of Health FIS-PI20/01681) and the research network CIBERCV (CB16/11/00479).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Mammalian TatD DNase domain containing 1 (TATDN1) is a proteostasis-responsive gene with roles in ventricular structure and neuromuscular function

  • Barés, Gisel
  • Beà Tàrrega, Aida
  • Sancho-Balsells, Anna
  • Valero, Juan Garcia
  • miro casas, elisabet
  • Ruiz Meana, Marisol
  • Aluja, David
  • Inserte, Javier
Cardiomyopathy; Motor control; Neurobehavior, Cardiomiopatía; Control motor; Neuroconducta, Cardiomiopatia; Control motor; Neuroconducta, The characterization of highly conserved but poorly understood genes often reveals unexpected biological roles, advancing our understanding of disease mechanisms. One such gene is Mammalian TatD DNase domain containing 1 (Tatdn1), the mammalian homolog of bacterial Twin-arginine translocation D (TatD), a protein proposed to have roles either in DNA degradation or protein quality control in unicellular organisms. Despite its association with different pathologies, including several cancer types and cardiovascular diseases, the role of TATDN1 in mammals remains unexplored. Here, we demonstrate that Tatdn1 encodes a cytoplasmic protein that does not participate in DNA degradation but is upregulated in cells under proteostasis stress. Tatdn1-deficient mice exhibit dysregulated expression of genes involved in membrane and extracellular protein biology, along with mild dilated cardiomyopathy and impaired motor coordination. These findings identify TATDN1 as a key player in cytosolic processes linked to protein homeostasis, with significant physiological implications for cardiac and neurological function., This research was funded by Ministerio de Ciencia, Innovación y Universidades, Gobierno de España, grant numbers PID2019-104509RB-I00 and PID2022-139965OB-100 to DS; Fundació La Marató TV3, grant number 20153810 to DS; AGAUR, Generalitat de Catalunya, grant number 2014-SGR-1609 to DS and JXC; GB holds a contract from the University of Lleida; AB holds a contract from Fundació La Marató TV3 and IRBLleida/Diputació de Lleida. SGC is the recipient of a FI Joan Oró contract from the Generalitat de Catalunya and co-financed by the European Social Fund Plus (FSE+) (AGAUR_2024_FI-1_00908) and AG is a Ramón y Cajal fellow (RYC-2016-19466) supported by a grant from Ministerio de Ciencia, Innovación y Universidades (PID2021-122258OB-I00). We thank the personnel of the University of Lleida Experimental Animal Service and Roser Pané for their technical assistance at IRBLleida and Ana López (María de Maeztu Unit of Excellence, Institute of Neurosciences, University of Barcelona, MDM-2017-0729, Ministerio de Ciencia, Innovación y Universidades) for technical support. We thank Dimitri Shcherbakov (Institut fur Medizinische Mikrobiologie, Universitat Zurich, Switzerland.) for his kind gift of HEK293 WT and RPS9 D95N mutant cells. JI and MRM are funded by Instituto de Salud Carlos III (ISCIII) (PI19-01196 and PI20-01681), CIBER-CV, and the European Regional Development Fundings (ERDF-FEDER). Work at The Novo Nordisk Foundation Center for Protein Research (CPR) is funded in part by a generous donation from the Novo Nordisk Foundation (Grant number NNF14CC0001) and from the European Union's Horizon 2020 research and innovation program under grant agreement EPIC-XS-823839.